| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/05/2004 | WO2004010996A1 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis |
| 02/05/2004 | WO2004010995A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 02/05/2004 | WO2004010994A1 Indometacin preparation for external use |
| 02/05/2004 | WO2004010993A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 02/05/2004 | WO2004010992A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | WO2004010991A1 Food improving blood flow |
| 02/05/2004 | WO2004010990A1 Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |
| 02/05/2004 | WO2004010989A1 Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals |
| 02/05/2004 | WO2004010988A1 Percutaneous and perungual delivery system |
| 02/05/2004 | WO2004010987A2 Use of s1p receptor agonists in heart diseases |
| 02/05/2004 | WO2004010986A1 Use of modulators of the signal transduction path using the protein kinase fyn for the treatment of tumorous diseases |
| 02/05/2004 | WO2004010984A2 Microcapsules with modified release of active principles with low solubility for oral delivery |
| 02/05/2004 | WO2004010982A1 Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
| 02/05/2004 | WO2004010981A1 Methods and dosage forms for controlled delivery of paliperidone |
| 02/05/2004 | WO2004010980A1 Compositions comprising hmg-coa reductase inhibitor |
| 02/05/2004 | WO2004010977A1 Method for decreasing bioavailability variability of an orally administered medicine |
| 02/05/2004 | WO2004010974A2 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | WO2004010973A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | WO2004010972A2 Pellicle-resistant gelatin capsule |
| 02/05/2004 | WO2004010970A1 Formulations and dosage forms for controlled delivery of topiramate |
| 02/05/2004 | WO2004010966A1 External preparation |
| 02/05/2004 | WO2004010965A1 Use of lignans for prevening or treating the sings of ageing of the skin |
| 02/05/2004 | WO2004010961A1 Oral humectants |
| 02/05/2004 | WO2004010955A2 Cyclooxygenase-2 inhibitors for appetite suppression |
| 02/05/2004 | WO2004010952A2 Methods and compositions for treatment of dermal conditions |
| 02/05/2004 | WO2004010950A2 Aryl substituted hydantoin compounds and their use as sodium channel blockers |
| 02/05/2004 | WO2004010948A2 Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
| 02/05/2004 | WO2004010946A2 Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
| 02/05/2004 | WO2004010945A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | WO2004010942A2 Substituted heterocyclic compounds as modulators of the ccr5 receptor |
| 02/05/2004 | WO2004010941A2 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 02/05/2004 | WO2004010938A2 Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure |
| 02/05/2004 | WO2004010937A2 Method of treating cancer |
| 02/05/2004 | WO2004010936A2 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | WO2004010929A2 METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS |
| 02/05/2004 | WO2004010928A2 Steroid modulators in the treatment of peripheral nerve sheath tumors |
| 02/05/2004 | WO2004010927A2 Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes |
| 02/05/2004 | WO2004010924A2 Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof |
| 02/05/2004 | WO2004010900A1 Devices delivering therapeutic agents and methods regarding the same |
| 02/05/2004 | WO2004010894A2 Ophthalmologic irrigation solutions and method |
| 02/05/2004 | WO2004010842A2 Lipophilic electrophoretic probes |
| 02/05/2004 | WO2003099228A8 Compositions and processes for inhibiting gene expression using polynucleotides |
| 02/05/2004 | WO2003099197A3 Formulations of erythromycin derivatives with improved bioavailability |
| 02/05/2004 | WO2003097644A3 Non-nucleoside reverse transcriptase inhibitors |
| 02/05/2004 | WO2003096968A3 Oral osmotic controlled drug delivery system |
| 02/05/2004 | WO2003094829A3 Pathogen vaccines and methods for using the same |
| 02/05/2004 | WO2003092589A3 Salt solution for colon cleansing |
| 02/05/2004 | WO2003089624A3 Fc receptor homolog, reagents, and uses thereof |
| 02/05/2004 | WO2003089001A8 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus |
| 02/05/2004 | WO2003087818A3 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 02/05/2004 | WO2003086293A3 Pharmaceutical preparation for taste masking |
| 02/05/2004 | WO2003084938A3 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases |
| 02/05/2004 | WO2003084560A3 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| 02/05/2004 | WO2003083442A3 Life sciences business systems and methods |
| 02/05/2004 | WO2003082255A3 Use of mob-5 in pain |
| 02/05/2004 | WO2003082247A3 Drug microparticles |
| 02/05/2004 | WO2003082244A3 Hfa-suspension formulation of an anhydrate |
| 02/05/2004 | WO2003080608A3 Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
| 02/05/2004 | WO2003080580A3 Quinoline derivatives and their use as 5-ht6 ligands |
| 02/05/2004 | WO2003080181A3 Storage stable eplerenone formulation |
| 02/05/2004 | WO2003076388A3 Bis-aniline derivatives useful as potassium channels modulators |
| 02/05/2004 | WO2003075857A3 Amino-methyl substituted tetracycline compounds |
| 02/05/2004 | WO2003074654A3 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 02/05/2004 | WO2003074062A3 Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals |
| 02/05/2004 | WO2003074006A3 Compositions and methods for preventing sporadic neoplasia in colon |
| 02/05/2004 | WO2003072038A3 COMPOSITIONS AND METHODS FOR INHIBITING NF-κB MEDIATED TUMORIGENICITY AND ADHESION-DEPENDENT SURVIVAL OF CANCER CELLS |
| 02/05/2004 | WO2003070703A3 Hydroxylated indirubin derivatives |
| 02/05/2004 | WO2003070167A3 Therapeutic and prophylactic treatment of aging and disorders of aging in humans |
| 02/05/2004 | WO2003066091A3 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 02/05/2004 | WO2003066067A3 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| 02/05/2004 | WO2003064455A3 Macrocyclic peptides active against the hepatitis c virus |
| 02/05/2004 | WO2003064388A3 Process for the preparation of high purity perindopril and intermediates useful in the synthesis |
| 02/05/2004 | WO2003063849A9 Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome |
| 02/05/2004 | WO2003052052A3 Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| 02/05/2004 | WO2003051348A3 Composition, synthesis and therapeutic applications of polyamines |
| 02/05/2004 | WO2003024386A3 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| 02/05/2004 | WO2003016915A8 Tumor specific oligosaccharide sequences and use thereof |
| 02/05/2004 | WO2002100886A8 Pyrrolidin-2-one derivatives as inhibitors of factor xa |
| 02/05/2004 | WO2002087555A3 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer |
| 02/05/2004 | WO2002072776A3 Cell culture system for synthesis of infectious hepatitis c virus |
| 02/05/2004 | WO2002041834A8 Atorvastatin hemi-calcium form vii |
| 02/05/2004 | WO2002018632A3 Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3' |
| 02/05/2004 | US20040025199 Comprises g-protein couple receptors for identifying modulators of g-protein activity and diagnosis and treatment of infections, nervous system, tumor, autoimmune and inflammatory disorders |
| 02/05/2004 | US20040025196 Comprises nucleotide sequences coding proteins with plenty of SH3 domains (POSH) for preventing viral and bacterial infection and replication; rational drug design; viricides; antiapoptosis agents; bactericides |
| 02/05/2004 | US20040024450 Drug-delivery endovascular stent and method for treating restenosis |
| 02/05/2004 | US20040024363 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/05/2004 | US20040024264 Process for the preparation of meso-zeaxanthin |
| 02/05/2004 | US20040024231 Such as 17-beta-hydroxy-17-alpha-trifluoromethyl-7-alpha-methyl-androst-4-en-3-one; for hormone replacement therapy |
| 02/05/2004 | US20040024224 Synthesis of 2-alkyl amino acids |
| 02/05/2004 | US20040024222 Such as 5-(4-(2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy)-benzo(b)thiophen-7 -ylmethyl)2,4-thiazolidinedione via bromo-/chloro-methylation; for treatment of diabetes |
| 02/05/2004 | US20040024220 Lipids |
| 02/05/2004 | US20040024218 Novel compounds |
| 02/05/2004 | US20040024217 Synthesis of piperidine and piperazine compounds as CCR5 antagonists |
| 02/05/2004 | US20040024215 Such as 4'-trifluoromethyl-biphenyl-2-carboxylic acid(4-(4-(alpha-methyl-benzyl)-piperazin-1-yl)-phenyl)-amide; apoprotein B-100 (apoB-100) and microsomal triglyceride transfer protein (MTP) |
| 02/05/2004 | US20040024214 Such as (R)-9-(2-(stearoyloxymethyl)-4-(L-valyloxy)butyl)-guanine for treatment of herpes and retroviral infections |
| 02/05/2004 | US20040024211 Such as (3S)-N-(2-(2-(2,4-dichlorophenyl)ethyl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl) -3-methyl-N'-((1S,2S,3S,5R)-2,6,6-trimethylbicyclo(3.1.1)hept-3 -yl)piperazine-1-carboximidamide for treatment of obesity or type II diabetes |
| 02/05/2004 | US20040024210 New compounds |
| 02/05/2004 | US20040024209 Drugs such as 4-(3-Bromo-4-fluorobenzyl)morpholine used as viricides against herpes viruses |
| 02/05/2004 | US20040024208 Cyclic protein tyrosine kinase inhibitors |
| 02/05/2004 | US20040024207 8'4-'3-(5Fluoro-1h-indol-3yl)propyl!-1-piperazinyl!-2-methyl-2h-1,4-benzoxazin-3(4h)-one methanesulfonate with high affinity for the dopamine d2 receptor and the seotonix reuptake site |